Skip to main content
HK inno.N Corporation logo

HK inno.N Corporation — Investor Relations & Filings

Ticker · 195940 ISIN · KR7195940002 KO Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country KR South Korea
Listing KO 195940

About HK inno.N Corporation

https://www.inno-n.com/eng

HK inno.N Corporation is a biohealth company engaged in the development, manufacturing, and distribution of pharmaceutical and consumer healthcare products. The company operates through two main divisions: Specialty Medicines and Health & Beauty (H&B). The Specialty Medicines division focuses on prescription drugs, with research and development centered on novel treatments for gastrointestinal diseases, immune diseases, and cancer. Its bio-research efforts also include vaccines and next-generation cell and gene therapies. The Health & Beauty division provides consumer products such as health functional foods and beauty items, supported by dedicated research into new materials and ingredients. The company leverages its integrated R&D capabilities to offer innovative solutions across both its pharmaceutical and consumer health markets.

Recent filings

Filing Released Lang Actions
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Regulatory Filings Classification · 87% confidence The document is an annual “enterprise group status” disclosure under Korean corporate regulations, showing group structure, financials, affiliate transactions, ESG and related‐party details. It is not an Annual or Interim Report (10-K/IR), not an earnings release, proxy statement or detailed management discussion, but rather a general compliance/regulatory filing. It best fits the fallback category Regulatory Filings (RNS).
2026-06-01 Korean
신규시설투자등
Regulatory Filings Classification · 85% confidence The document is a corporate announcement detailing a new facility investment project (investment amount, purpose, timelines, board resolution), not a fundraising or capital structure change, nor a dividend, share issuance, or annual/interim report. It does not fit any specialized category (e.g., CAP is for financing updates, SHA for share issues), so it is best classified under the general Regulatory Filings (RNS) fallback.
2026-05-21 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled ‘분기보고서’ (Quarterly Report) covering the period 2026.01.01–2026.03.31, and contains detailed financial statements and business analysis for the quarter. It is clearly the full interim/quarterly report itself (with actual financial data), not just an announcement. This matches the definition for an Interim/Quarterly Report (IR). Q1 2026
2026-05-14 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (경증에서 중등증 아토피 피부염 치료 후보물질 IN-115314 임상 1b상 임상시험계획(IND) 미국 식품의약국(FDA) 승인)
Regulatory Filings Classification · 75% confidence The document is a Korean ‘투자판단 관련 주요경영사항’ disclosure detailing the FDA approval of a clinical trial plan for a drug candidate. It is a statutory material event announcement rather than a financial report, earnings release, management discussion, or other specific filing type. It does not contain substantive financial statements or analysis, and it is not simply notifying the publication of a separate report. Therefore it falls under Regulatory Filings (RNS), the catch-all category for miscellaneous regulatory disclosures.
2026-05-13 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 82% confidence The document is a concise public disclosure of provisional operating results (“영업(잠정)실적(공정공시)”) for the quarter ended March 31, 2026. It presents key financial metrics—revenues, operating profit, pre-tax income, net income—alongside comparisons to prior periods. The format and brevity (under 5,000 characters) indicate an initial quarterly earnings announcement rather than a full interim report. This matches the definition of an Earnings Release (ER). Q1 2026
2026-04-28 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 70% confidence The document is an announcement of an upcoming investor relations conference call detailing date, time, purpose (Q1 2026 results), venue, participants, and how materials will be posted. It is not the actual presentation slides (IP), nor the financial report (IR), but a general regulatory notice about an IR event. Therefore, it best fits the fallback category for miscellaneous regulatory announcements.
2026-04-28 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.